|
| 汉曲优?与赫赛汀?新辅助治疗早期HER2阳性乳腺癌的临床应用分析:一项回顾性队列研究 |
| Qian Hu1 Haibo Duan1 Ruilin Pan2 Litao Li1 Feng Peng2 Xiuyun Chen1 Yingxin Lin1 Fengtao Pan1 Danmei Pang1*1Department of oncology,Foshan No.1 hospital,Foshan 528000,China |
| 投稿时间：2024-05-15 修订日期：2025-02-09 |
| DOI： |
|
 |
| 中文关键词: 汉曲优? 赫赛汀? HER2阳性乳腺癌 病理学完全缓解 安全性 |
| 英文关键词:Zercepac? Herceptin? HER2-positive breast cancer Pathologic complete response Safety |
| 基金项目: |
|
| 摘要点击次数: 17 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：比较汉曲优?与赫赛汀?新辅靶向治疗联合化疗治疗早期人表皮生长因子受体-2（human epidermal growth factor receptor-2，HER2）阳性乳腺癌的疗效和安全性，并探究可能影响患者新辅助治疗后病理学完全缓解（pathologic complete response，pCR）的风险因素。方法：回顾性纳入2020年12月~2021年11月在佛山市第一人民医院乳腺外科及乳腺肿瘤内科接受曲妥珠单抗新辅助靶向治疗联合化疗的早期HER2阳性乳腺癌患者，评估患者pCR率，统计新辅助治疗期间不良事件发生情况，并采用Logistic回归分析影响新辅助治疗后患者pCR的独立风险因素。结果：最终纳入93例患者分析，汉曲优?组为34例，赫赛汀?组为59例。接受新辅助治疗后，汉曲优?组和赫赛汀?组的pCR率分别为64.7%和58.3%，无统计学差异（P=0.608）。单因素logistic回归分析结果显示，相比曲妥珠单抗单药治疗，曲妥珠单抗和帕妥珠单抗联合化疗的患者相比曲妥珠单抗联合化疗的患者pCR更高，具有统计学意义（OR=4.205，95%CI 1.720-10.277，P=0.002）。在安全性方面，汉曲优?组和赫赛汀?组不良事件发生率分别为44.1%和52.5%，无统计学差异（P=0.434）。结论：接受汉曲优新辅助靶向治疗联合化疗的患者和接受赫赛汀和联合化疗的患者pCR获益和安全性无统计学学差异，联合使用帕妥珠单抗可能更有助于患者达到pCR。 |
| 英文摘要: |
| Objective: This study aimed to compare the efficacy and safety of Zercepac? and Herceptin? in neoadjuvant targeted therapy combined with chemotherapy for early-stage human epidermal growth factor receptor-2 (HER2)-positive breast cancer and to investigate the risk factors that may affect the pathologic complete response (pCR) of patients after neoadjuvant therapy. Methods: Patients with early-stage HER2-positive breast cancer who received trastuzumab in neoadjuvant targeted therapy combined with chemotherapy in the Department of Breast Surgery and Breast Oncology, Foshan No.1 People"s Hospital from December 2020 to November 2021 were retrospectively included. Their pCR rate was evaluated, the incidence of adverse events during the neoadjuvant therapy was calculated, and the independent risk factors affecting the pCR were analyzed using logistic regression. Results: A total of 93 patients were included, 34 in the Zercepac? group and 59 in the Herceptin? group. After receiving the neoadjuvant therapy, the Zercepac? and Herceptin? groups recorded a pCR rate of 64.7% and 58.3%, with no statistical difference (P = 0.608). According to the univariate logistic regression analysis, trastuzumab and pertuzumab combined with chemotherapy produced higher pCR than trastuzumab combined with chemotherapy, with statistical difference (OR = 4.205, 95%CI 1.720-10.277, P = 0.002). Regarding safety, the incidence of adverse events in the Zercepac? and Herceptin? groups was 44.1% and 52.5%, with no statistical difference (P = 0.434). Conclusion: There was no significant difference in pCR benefit and safety between patients receiving Zercepac? in neoadjuvant targeted therapy combined with chemotherapy and thsoe undergoing Herceptin? combined with chemotherapy. Additionally, combining with pertuzumab may better help patients achieve pCR. |
|
在线阅读
查看/发表评论 下载PDF阅读器 |
|
|
|